TY - JOUR
T1 - Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma
T2 - Report of a phase II trial
AU - Gupta, S.
AU - Zhou, P.
AU - Hassoun, H.
AU - Kewalramani, T.
AU - Reich, L.
AU - Costello, S.
AU - Drake, L.
AU - Klimek, V.
AU - Dhodapkar, M.
AU - Teruya-Feldstein, J.
AU - Hedvat, C.
AU - Kalakonda, N.
AU - Fleisher, M.
AU - Filippa, D.
AU - Qin, J.
AU - Nimer, S. D.
AU - Comenzo, R. L.
N1 - Funding Information:
patients. This work was supported by NIH Grant CA05826, FDA Grant R01-002174-02 (RLC), the Graziano Fund, the Multiple Myeloma Research Foundation, the Mel Stottlemyre Myeloma Research Fund, the Donald Stein Myeloma Research Fund, the Werner and Elaine Dannheiser Fund for Research on the Biology of Aging of the Lymphoma Foundation, and Amgen.
PY - 2005/3
Y1 - 2005/3
N2 - Multiple myeloma (MM) is an incurable hematologic malignancy for which autologous hematopoietic stem cell transplantation (HCT) is a standard therapy. The optimal method of stem cell mobilization is not defined. We evaluated intravenous melphalan (60 mg/m2), the most effective agent for MM, and G-CSF (10 μg/kg/day) for mobilization. End points were safety, adequacy of CD34 + collections, MM response, and contamination of stem cell components (SCC). In total, 32 patients were mobilized. There were no deaths or significant bleeding episodes; 14 patients (44%) required hospitalization for neutropenic fever. Median days of grade 3 or 4 neutropenia or thrombocytopenia were 7 (2-20) and 8 (3-17). Median mobilization days, CD34 + cells/kg and total leukaphereses were 16 (12-30), 12.1 million (2.6-52.8), and 2 (1-5) respectively. Four patients (12.5 %) failed to achieve the target of 4 million CD34 + cells/kg in five leukaphereses. Reduction in myeloma was seen in 11 patients (34%) with 3 (9%) achieving complete response; 15 (47%) maintained prior responses. Estimated MM contamination per SCC (N=48) was 0.0009% (range 0-0.1) and 0.21 × 10 4 cells per kg (range 0-41.2). Increased contamination was associated with increased patient age. This strategy for mobilization is feasible, frequently requires hospitalization and transfusion, and controls disease in most patients.
AB - Multiple myeloma (MM) is an incurable hematologic malignancy for which autologous hematopoietic stem cell transplantation (HCT) is a standard therapy. The optimal method of stem cell mobilization is not defined. We evaluated intravenous melphalan (60 mg/m2), the most effective agent for MM, and G-CSF (10 μg/kg/day) for mobilization. End points were safety, adequacy of CD34 + collections, MM response, and contamination of stem cell components (SCC). In total, 32 patients were mobilized. There were no deaths or significant bleeding episodes; 14 patients (44%) required hospitalization for neutropenic fever. Median days of grade 3 or 4 neutropenia or thrombocytopenia were 7 (2-20) and 8 (3-17). Median mobilization days, CD34 + cells/kg and total leukaphereses were 16 (12-30), 12.1 million (2.6-52.8), and 2 (1-5) respectively. Four patients (12.5 %) failed to achieve the target of 4 million CD34 + cells/kg in five leukaphereses. Reduction in myeloma was seen in 11 patients (34%) with 3 (9%) achieving complete response; 15 (47%) maintained prior responses. Estimated MM contamination per SCC (N=48) was 0.0009% (range 0-0.1) and 0.21 × 10 4 cells per kg (range 0-41.2). Increased contamination was associated with increased patient age. This strategy for mobilization is feasible, frequently requires hospitalization and transfusion, and controls disease in most patients.
UR - http://www.scopus.com/inward/record.url?scp=20144386351&partnerID=8YFLogxK
U2 - 10.1038/sj.bmt.1704779
DO - 10.1038/sj.bmt.1704779
M3 - Article
C2 - 15640822
AN - SCOPUS:20144386351
SN - 0268-3369
VL - 35
SP - 441
EP - 447
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 5
ER -